C2N Diagnostics receives $15M investment to advance its blood test for Alzheimer's disease
The biotechnology startup plans to use its funding to develop a second version of its blood test that aims to help diagnose Alzheimer's disease.
C2N stated that the funding came from the GHR Foundation. This foundation focuses on Alzheimer’s prevention and builds on a $20 million GHR investment in 2020. C2N will have Fred Miller, GHR Chief Operating Officer, and Managing Director for Biomedical Programmes, as a board observer.